Psoriatic Arthritis

Types of occupation did not significantly affect response to treatment.

This interview at the Fall 2024 Maui Derm conference features Melodie Young, with a discussion about updates in psoriasis and psoriatic arthritis therapy for children.

There were no differences in risk between patients with RA or PsA using or not using methotrexate.

Wells discussed the PrismRA blood test, which may benefit planning treatment regimens for patients with rheumatic disease.

Wells discussed the importance and recommended frequency for several factors, including lipid panels, chest X-rays, pregnancy tests, and flu vaccines.

This feature highlights the views of 3 experts on the integration of patient-reported outcomes into the management of psoriatic disease.

Investigators analyzed levels of CXCL10, MMP3, S100A8, ACP5, and CCL2 in patients treated with biologics and methotrexate.

Mease went over research initiatives including the ARGO, AXIS, and STAR studies.

Mease discussed data supporting FDA approval for the indications in Fall 2024.

Higher risk associations also included being a current smoker and socioeconomic deprivation.

More patients also switched from combination therapy to monotherapy at any time in both analyzed database populations.

Around 20% of participants had ultrasound evidence of at least 1 active enthesitis, and 15.7% had ultrasound signs of at least 1 active synovitis at examination.

A recent study showed an association between pediatric acute-onset neuropsychiatric syndrome and inflammatory diathesis.

A separate paper also found that the overall risk of serious infection was low in new users of targeted therapy.

A retrospective analysis compared data from the BE OPTIMAL and BE COMPLETE trials with data from pivotal trials of the IL-23–targeting therapies.

Similar trends were seen in study participants that transitioned from receiving placebo to bimekizumab after study week 16.

Medical experts engage in a discussion surrounding the treatment and management of patients diagnosed with psoriasis and psoriatic arthritis.

Subjects reported pain at the injection site was significantly reduced with the One-Press autoinjector pen and 98% chose the pen as their preferred medication delivery system.

Responders at week 104 demonstrated more significant changes from baseline and achieved normative values in PROs compared with non-responders.

Patients with inflammatory arthritis experiencing “long COVID” reported significantly worse disease activity.

Patients with lower levels of physical activity had higher levels of fatigue and a higher risk of sarcopenia.

PASI100 was achieved by 41.7% of patients at week 16 and 70.6% at week 260.

Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.

Most men (91.7%) and women (72.7%) with psoriatic arthritis exhibited sexual dysfunction.

Independent predictors of physical activity avoidance were anxiety symptoms—as determined by HADS—and the SF-36 Physical Component Score.